Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results

Actively enrolling participants in our Phase 2/3 clinical trial for the potential treatment of progressive NF2-mutated meningiomasOn track to init...

Related Keywords

Montreal ,Quebec ,Canada ,Salt Lake City ,Utah ,United States ,Toronto ,Ontario ,Chris Gibson ,Development Expenses ,Genentech ,Recursion Pharmaceuticals Inc ,European Commission ,Drug Administration ,European Commission Orphan Drug ,Children Tumor Foundation Nf Conference ,Recursion Fast Track ,Recursion Orphan Drug Designation ,Pipeline Programs ,Tumor Foundation ,Therapeutic Data Commons ,Administrative Expenses ,San Francisco Bay ,Consolidated Statements ,Consolidated Balance Sheets ,